Next 10 |
Asserts Arbutus’ Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further Share Issuances and Plans to Vote AGAINST Proposed Share Incre...
2024-05-02 13:15:20 ET Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Conference Call May 2, 2024 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations Mike McElhaugh - Interim President and Chief Executive Officer and Director ...
2024-05-02 07:33:05 ET More on Arbutus Biopharma Moderna Investors Should Beware Patent-Dispute Fallout Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutu...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepa...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-05-01 11:46:16 ET More on Arbutus Biopharma Moderna Investors Should Beware Patent-Dispute Fallout Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutu...
2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...
2024-04-23 14:40:54 ET Summary Moderna's stock rose after positive results from its cancer vaccine trial, but legal issues could lead to a massive judgment against the company. Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensi...
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Asserts Arbutus’ Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further Share Issuances and Plans to Vote AGAINST Proposed Share Incre...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...